Displaying drugs 15126 - 15150 of 15703 in total
Litoxetine
Litoxetine is under investigation in clinical trial NCT03397771 (DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence).
Investigational
Matched Description: … under investigation in clinical trial NCT03397771 (DBPC Trial to Evaluate the Safety, Tolerability and …
MK-6325
MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)).
Investigational
Matched Description: … MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics …
Ensifentrine
Ensifentrine is under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD).
Investigational
Matched Description: … under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and …
Olacaftor
Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis).
Investigational
Matched Description: … Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy …
Arketamine
Arketamine is under investigation in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and Efficacy of PCN-101 in TRD).
Investigational
Matched Description: … in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and …
CMC 001
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Investigational
Matched Description: … is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and …
Fludeoxyglucose
Fludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma).
Investigational
Matched Description: … Fludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 …
Fosmanogepix
Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).
Investigational
Matched Description: … Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 …
Emprumapimod
Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
Investigational
Matched Description: … Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor …
Ensitrelvir
Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).
Investigational
Matched Description: … Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory …
Rifasutenizol
Rifasutenizol is under investigation in clinical trial NCT05857163 (Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection).
Investigational
Matched Description: … Rifasutenizol is under investigation in clinical trial NCT05857163 (Efficacy and Safety of Rifasutenizol …
2-Amino-3-(1h-Indol-3-Yl)-Propan-1-Ol
Experimental
Arimoclomol
Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
Investigational
Pipendoxifene
ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment for metastatic breast cancer.
Investigational
Matched Description: … estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and …
4-O-Demethylpenclomedine
Investigational
2-heptyl-4-hydroxyquinoline N-oxide
Experimental
9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE
Experimental
(3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE
Experimental
Thiacloprid
Experimental
Displaying drugs 15126 - 15150 of 15703 in total